HERON THERAPEUTICS INC. news, videos and press releases - Page 5
For more news please use our advanced search feature.
HERON THERAPEUTICS INC. - More news...
HERON THERAPEUTICS INC. - More news...
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Heron Therapeutics, Inc. - HRTX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Heron Therapeutics, Inc. - HRTX
- Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain
- Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management
- 77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy
- Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference
- Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push
- Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress
- Heron Therapeutics to Present at the 8th Annual Leerink Partners Global Healthcare Conference
- Heron Therapeutics Announces Retirement of Robert Rosen as President
- Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
- 90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study
- Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
- FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management
- Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference
- U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics
- Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress
- Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management
- Heron Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
- Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
- Recent Analysis Shows Premier, Quantum, Heron Therapeutics, Dillard's, LightPath Technologies, and Ichor Market Influences — Renewed Outlook, Key Drivers of Growth